HRAS G12V

CI-VAR-00001622Explore in graph →CIViC 1394

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Head and Neck Squamous Cell Carcinoma1
HRAS G12V	Alpelisib	Predictive	D	Supports Resistance	1	submitted	EID9087 In this preclinical study, cell lines with constitutively-active G12V mutant found that forced overexpression of HRAS G12V caused a reduced susceptibility to PI3K inhibitor BYL719 in comparison to wil… (full text at CIViC) PMID 30115483 · Ruicci et al., 2018 · Open in CIViC	civic
Malignant Colorectal Neoplasm1
HRAS G12V	Cetuximab	Predictive	D	Supports Resistance	—	submitted	EID3855 In an in vitro study, DiFi colorectal cancer cell lines stably expressing HRAS G12V mutation demonstrated resistance to cetuximab treatment compared to DiFi cells expressing wild-type HRAS. Resistance… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Head and Neck Neoplasm1
HRAS G12V	Erlotinib	Predictive	D	Supports Resistance	—	submitted	EID3854 In an in vitro study, UM-SCC-10B, UM-SCC-22A and HN5 cell lines expressing HRAS G12V mutation demonstrated decreased sensitivity to erlotinib treatment compared to the respective sensitive parental ce… (full text at CIViC) PMID 24123531 · Hah et al., 2014 · Open in CIViC	civic

Malignant Neoplasm1
HRAS Q61L OR HRAS Q61R OR HRAS G12V	Binimetinib + Everolimus + Mirdametinib + MTOR Kinase Inhibitor AZD8055 + SelumetinibSubstitutes	Predictive	D	Supports Sensitivity Response	3	accepted	EID700 In preclinical cancer cell line and Ba/F3 models, HRAS Q61L, Q61R, and G12V mutations conferred sensitivity to MEK inhibitors (AZD6244/selumetinib, MEK162/binimetinib, and PD0325901) and mTOR inhibito… (full text at CIViC) PMID 26544513 · Kiessling et al., 2015 · Open in CIViC	civic